Eli Lilly has submitted its coronavirus antibody treatment to the Food and Drug Administration for emergency authorization. The drug, LY-CoV555, reduced hospitalization rates for patients with COVID-19. When combined with the drugmaker’s other COVID-19 treatment, LY-CoV016, had similar results. (CNBC)
Patients hospitalized with the coronavirus have a heightened risk of developing dangerous blood clots. New analysis of multiple studies found that 23% of patients in the ICU developed a deep vein thrombosis. (WebMD)
Antibiotics may be the best treatment to administer first to appendicitis patients, according to a large U.S. trial. More than 70% of the patients in the trial who received antibiotics were able to avoid surgery for at least 90 days. (WebMD)
Coronavirus patients frequently develop myocarditis, according to a study published in JAMA Cardiology. Researchers discovered that 78 out of 100 patients recovering from COVID-19 had cardiac impairment. Sicty had myocarditis, independent of whether or not they have a pre-existing condition or the severity of their COVID symptoms. (U.S. News)
The 2020 MM+M Awards take place today. Join us virtually to celebrate the best in healthcare marketing. (MM+M)
